Biogen, Sage

Sage Therapeutics' financials indicate a need for additional funding in 2025, risking dilution and further financial ...
Sage stock rose 35% to $7.51 in premarket trading Monday; it closed at $5.55 on Friday. Biogen shares dipped 0.5% to $48.01.
Analysts say the deal, which would give Biogen full control over the drug Zurzuvae, could be a smart financial move. Yet it's ...
A yearslong partner of neuroscience player Sage, Biogen already owns 10.2% of the Cambridge, Massachusetts-based biotech, ...
Biogen is looking to augment growth by hunting for biotechs with drugs in mid- and late-stage clinical development.
Biogen expects revenue from new launches to exceed its current sales by 2028 and does not feel the need to chase additional ...